 | • レポートコード：MRC2012A6891 • 出版社/出版日：GlobalInfoResearch / 2020年12月24日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、PEG化医薬品の世界市場を広く調査・分析し、今後の市場展望をまとめております。PEG化医薬品の種類別市場規模（リンカー、クロスリンカー、その他）、用途別市場規模（がん、慢性腎臓病、肝炎、多発性硬化症、血友病、胃腸障害）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Thermo Fisher Scientific、Creative PEGworks、Merck、Iris Biotech Laysan Bio、Johnson & Johnson、Quanta BioDesign Celares Biomatrik、NOF、 ・地域別グローバル市場分析 2015年-2020年 ・PEG化医薬品の北米市場（アメリカ、カナダ、メキシコ） ・PEG化医薬品のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・PEG化医薬品のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・PEG化医薬品の南米市場（ブラジル、アルゼンチン） ・PEG化医薬品の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：リンカー、クロスリンカー、その他 ・用途別分析：がん、慢性腎臓病、肝炎、多発性硬化症、血友病、胃腸障害 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global PEGylated Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.7% in the forecast period of 2020 to 2025 and will expected to reach USD 8020.8 million by 2025, from USD 7206.3 million in 2019.
The PEGylated Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
PEGylated Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, PEGylated Drugs market has been segmented into
Linkers
Cross-Linkers
Other
By Application, PEGylated Drugs has been segmented into:
Cancer
Chronic Kidney Diseases
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorders
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global PEGylated Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level PEGylated Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global PEGylated Drugs market.
The report offers in-depth assessment of the growth and other aspects of the PEGylated Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and PEGylated Drugs Market Share Analysis
PEGylated Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, PEGylated Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the PEGylated Drugs sales, revenue and market share for each player covered in this report.
The major players covered in PEGylated Drugs are:
Thermo Fisher Scientific
Creative PEGworks
Merck
Iris Biotech Laysan Bio
Johnson & Johnson
Quanta BioDesign Celares Biomatrik
NOF
Among other players domestic and global, PEGylated Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PEGylated Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PEGylated Drugs, with price, sales, revenue and global market share of PEGylated Drugs in 2018 and 2019.
Chapter 3, the PEGylated Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PEGylated Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, PEGylated Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe PEGylated Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 PEGylated Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global PEGylated Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Linkers
1.2.3 Cross-Linkers
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global PEGylated Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Cancer
1.3.3 Chronic Kidney Diseases
1.3.4 Hepatitis
1.3.5 Multiple Sclerosis
1.3.6 Hemophilia
1.3.7 Gastrointestinal Disorders
1.4 Overview of Global PEGylated Drugs Market
1.4.1 Global PEGylated Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Thermo Fisher Scientific
2.1.1 Thermo Fisher Scientific Details
2.1.2 Thermo Fisher Scientific Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Thermo Fisher Scientific SWOT Analysis
2.1.4 Thermo Fisher Scientific Product and Services
2.1.5 Thermo Fisher Scientific PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Creative PEGworks
2.2.1 Creative PEGworks Details
2.2.2 Creative PEGworks Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Creative PEGworks SWOT Analysis
2.2.4 Creative PEGworks Product and Services
2.2.5 Creative PEGworks PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Merck SWOT Analysis
2.3.4 Merck Product and Services
2.3.5 Merck PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Iris Biotech Laysan Bio
2.4.1 Iris Biotech Laysan Bio Details
2.4.2 Iris Biotech Laysan Bio Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Iris Biotech Laysan Bio SWOT Analysis
2.4.4 Iris Biotech Laysan Bio Product and Services
2.4.5 Iris Biotech Laysan Bio PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Johnson & Johnson SWOT Analysis
2.5.4 Johnson & Johnson Product and Services
2.5.5 Johnson & Johnson PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Quanta BioDesign Celares Biomatrik
2.6.1 Quanta BioDesign Celares Biomatrik Details
2.6.2 Quanta BioDesign Celares Biomatrik Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Quanta BioDesign Celares Biomatrik SWOT Analysis
2.6.4 Quanta BioDesign Celares Biomatrik Product and Services
2.6.5 Quanta BioDesign Celares Biomatrik PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 NOF
2.7.1 NOF Details
2.7.2 NOF Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 NOF SWOT Analysis
2.7.4 NOF Product and Services
2.7.5 NOF PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global PEGylated Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global PEGylated Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 PEGylated Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 PEGylated Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global PEGylated Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global PEGylated Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global PEGylated Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America PEGylated Drugs Sales and Growth Rate (2015-2020)
4.3 Europe PEGylated Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific PEGylated Drugs Sales and Growth Rate (2015-2020)
4.5 South America PEGylated Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa PEGylated Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America PEGylated Drugs Sales, Revenue and Market Share by Country
5.1.1 North America PEGylated Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America PEGylated Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States PEGylated Drugs Sales and Growth Rate (2015-2020)
5.3 Canada PEGylated Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico PEGylated Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe PEGylated Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe PEGylated Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe PEGylated Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany PEGylated Drugs Sales and Growth Rate (2015-2020)
6.3 UK PEGylated Drugs Sales and Growth Rate (2015-2020)
6.4 France PEGylated Drugs Sales and Growth Rate (2015-2020)
6.5 Russia PEGylated Drugs Sales and Growth Rate (2015-2020)
6.6 Italy PEGylated Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific PEGylated Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific PEGylated Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific PEGylated Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China PEGylated Drugs Sales and Growth Rate (2015-2020)
7.3 Japan PEGylated Drugs Sales and Growth Rate (2015-2020)
7.4 Korea PEGylated Drugs Sales and Growth Rate (2015-2020)
7.5 India PEGylated Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia PEGylated Drugs Sales and Growth Rate (2015-2020)
7.7 Australia PEGylated Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America PEGylated Drugs Sales, Revenue and Market Share by Country
8.1.1 South America PEGylated Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America PEGylated Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil PEGylated Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina PEGylated Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa PEGylated Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa PEGylated Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa PEGylated Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia PEGylated Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey PEGylated Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt PEGylated Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa PEGylated Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global PEGylated Drugs Sales and Market Share by Type (2015-2020)
10.2 Global PEGylated Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global PEGylated Drugs Price by Type (2015-2020)
11 Global PEGylated Drugs Market Segment by Application
11.1 Global PEGylated Drugs Sales Market Share by Application (2015-2020)
11.2 Global PEGylated Drugs Revenue Market Share by Application (2015-2020)
11.3 Global PEGylated Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global PEGylated Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 PEGylated Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America PEGylated Drugs Market Forecast (2021-2025)
12.2.2 Europe PEGylated Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific PEGylated Drugs Market Forecast (2021-2025)
12.2.4 South America PEGylated Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa PEGylated Drugs Market Forecast (2021-2025)
12.3 PEGylated Drugs Market Forecast by Type (2021-2025)
12.3.1 Global PEGylated Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global PEGylated Drugs Market Share Forecast by Type (2021-2025)
12.4 PEGylated Drugs Market Forecast by Application (2021-2025)
12.4.1 Global PEGylated Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global PEGylated Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global PEGylated Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of PEGylated Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global PEGylated Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors
Table 8. Thermo Fisher Scientific PEGylated Drugs Major Business
Table 9. Thermo Fisher Scientific PEGylated Drugs Total Revenue (USD Million) (2017-2018)
Table 10. Thermo Fisher Scientific SWOT Analysis
Table 11. Thermo Fisher Scientific PEGylated Drugs Product and Services
Table 12. Thermo Fisher Scientific PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Creative PEGworks Basic Information, Manufacturing Base and Competitors
Table 14. Creative PEGworks PEGylated Drugs Major Business
Table 15. Creative PEGworks PEGylated Drugs Total Revenue (USD Million) (2017-2018)
Table 16. Creative PEGworks SWOT Analysis
Table 17. Creative PEGworks PEGylated Drugs Product and Services
Table 18. Creative PEGworks PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Merck Basic Information, Manufacturing Base and Competitors
Table 20. Merck PEGylated Drugs Major Business
Table 21. Merck PEGylated Drugs Total Revenue (USD Million) (2017-2018)
Table 22. Merck SWOT Analysis
Table 23. Merck PEGylated Drugs Product and Services
Table 24. Merck PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Iris Biotech Laysan Bio Basic Information, Manufacturing Base and Competitors
Table 26. Iris Biotech Laysan Bio PEGylated Drugs Major Business
Table 27. Iris Biotech Laysan Bio PEGylated Drugs Total Revenue (USD Million) (2017-2018)
Table 28. Iris Biotech Laysan Bio SWOT Analysis
Table 29. Iris Biotech Laysan Bio PEGylated Drugs Product and Services
Table 30. Iris Biotech Laysan Bio PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 32. Johnson & Johnson PEGylated Drugs Major Business
Table 33. Johnson & Johnson PEGylated Drugs Total Revenue (USD Million) (2017-2018)
Table 34. Johnson & Johnson SWOT Analysis
Table 35. Johnson & Johnson PEGylated Drugs Product and Services
Table 36. Johnson & Johnson PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Quanta BioDesign Celares Biomatrik Basic Information, Manufacturing Base and Competitors
Table 38. Quanta BioDesign Celares Biomatrik PEGylated Drugs Major Business
Table 39. Quanta BioDesign Celares Biomatrik PEGylated Drugs Total Revenue (USD Million) (2017-2018)
Table 40. Quanta BioDesign Celares Biomatrik SWOT Analysis
Table 41. Quanta BioDesign Celares Biomatrik PEGylated Drugs Product and Services
Table 42. Quanta BioDesign Celares Biomatrik PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. NOF Basic Information, Manufacturing Base and Competitors
Table 44. NOF PEGylated Drugs Major Business
Table 45. NOF PEGylated Drugs Total Revenue (USD Million) (2017-2018)
Table 46. NOF SWOT Analysis
Table 47. NOF PEGylated Drugs Product and Services
Table 48. NOF PEGylated Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Global PEGylated Drugs Sales by Manufacturer (2018-2019) (K Units)
Table 50. Global PEGylated Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 51. Global PEGylated Drugs Sales by Regions (2015-2020) (K Units)
Table 52. Global PEGylated Drugs Sales Market Share by Regions (2015-2020)
Table 53. Global PEGylated Drugs Revenue by Regions (2015-2020) (USD Million)
Table 54. North America PEGylated Drugs Sales by Countries (2015-2020) (K Units)
Table 55. North America PEGylated Drugs Sales Market Share by Countries (2015-2020)
Table 56. North America PEGylated Drugs Revenue by Countries (2015-2020) (USD Million)
Table 57. North America PEGylated Drugs Revenue Market Share by Countries (2015-2020)
Table 58. Europe PEGylated Drugs Sales by Countries (2015-2020) (K Units)
Table 59. Europe PEGylated Drugs Sales Market Share by Countries (2015-2020)
Table 60. Europe PEGylated Drugs Revenue by Countries (2015-2020) (USD Million)
Table 61. Asia-Pacific PEGylated Drugs Sales by Regions (2015-2020) (K Units)
Table 62. Asia-Pacific PEGylated Drugs Sales Market Share by Regions (2015-2020)
Table 63. Asia-Pacific PEGylated Drugs Revenue by Regions (2015-2020) (USD Million)
Table 64. South America PEGylated Drugs Sales by Countries (2015-2020) (K Units)
Table 65. South America PEGylated Drugs Sales Market Share by Countries (2015-2020)
Table 66. South America PEGylated Drugs Revenue by Countries (2015-2020) (USD Million)
Table 67. South America PEGylated Drugs Revenue Market Share by Countries (2015-2020)
Table 68. Middle East & Africa PEGylated Drugs Sales by Countries (2015-2020) (K Units)
Table 69. Middle East & Africa PEGylated Drugs Sales Market Share by Countries (2015-2020)
Table 70. Middle East & Africa PEGylated Drugs Revenue by Countries (2015-2020) (USD Million)
Table 71. Middle East & Africa PEGylated Drugs Revenue Market Share by Countries (2015-2020)
Table 72. Global PEGylated Drugs Sales by Type (2015-2020) (K Units)
Table 73. Global PEGylated Drugs Sales Share by Type (2015-2020)
Table 74. Global PEGylated Drugs Revenue by Type (2015-2020) (USD Million)
Table 75. Global PEGylated Drugs Revenue Share by Type (2015-2020)
Table 76. Global PEGylated Drugs Sales by Application (2015-2020) (K Units)
Table 77. Global PEGylated Drugs Sales Share by Application (2015-2020)
Table 78. Global PEGylated Drugs Sales Forecast by Regions (2021-2025) (K Units)
Table 79. Global PEGylated Drugs Market Share Forecast by Regions (2021-2025)
Table 80. Global PEGylated Drugs Sales Forecast by Type (2021-2025) (K Units)
Table 81. Global PEGylated Drugs Market Share Forecast by Type (2021-2025)
Table 82. Global PEGylated Drugs Sales Forecast by Application (2021-2025)
Table 83. Global PEGylated Drugs Market Share Forecast by Application (2021-2025)
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Distributors/Traders/ Dealers List
List of Figures
Figure 1. PEGylated Drugs Picture
Figure 2. Global Sales Market Share of PEGylated Drugs by Type in 2019
Figure 3. Linkers Picture
Figure 4. Cross-Linkers Picture
Figure 5. Other Picture
Figure 6. PEGylated Drugs Sales Market Share by Application in 2018
Figure 7. Cancer Picture
Figure 8. Chronic Kidney Diseases Picture
Figure 9. Hepatitis Picture
Figure 10. Multiple Sclerosis Picture
Figure 11. Hemophilia Picture
Figure 12. Gastrointestinal Disorders Picture
Figure 13. Global PEGylated Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey PEGylated Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global PEGylated Drugs Sales Market Share by Manufacturer in 2019
Figure 34. Global PEGylated Drugs Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 PEGylated Drugs Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 PEGylated Drugs Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 39. Global PEGylated Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global PEGylated Drugs Revenue Market Share by Regions (2015-2020)
Figure 41. Global PEGylated Drugs Revenue Market Share by Regions in 2018
Figure 42. North America PEGylated Drugs Sales and Growth Rate (2015-2020)
Figure 43. Europe PEGylated Drugs Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific PEGylated Drugs Sales and Growth Rate (2015-2020)
Figure 45. South America PEGylated Drugs Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa PEGylated Drugs Sales and Growth Rate (2015-2020)
Figure 47. North America PEGylated Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America PEGylated Drugs Sales Market Share by Countries (2015-2020)
Figure 49. North America PEGylated Drugs Sales Market Share by Countries in 2018
Figure 50. North America PEGylated Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America PEGylated Drugs Revenue Market Share by Countries in 2018
Figure 52. United States PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Canada PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 54. Mexico PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 55. Europe PEGylated Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe PEGylated Drugs Revenue Market Share by Countries (2015-2020)
Figure 57. Europe PEGylated Drugs Revenue Market Share by Countries in 2019
Figure 58. Germany PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 59. UK PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 60. France PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Russia PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 62. Italy PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Asia-Pacific PEGylated Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific PEGylated Drugs Sales Market Share by Regions 2019
Figure 65. Asia-Pacific PEGylated Drugs Revenue Market Share by Regions 2019
Figure 66. China PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 67. Japan PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 68. Korea PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 69. India PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 70. Southeast Asia PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 71. South America PEGylated Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America PEGylated Drugs Sales Market Share by Countries in 2019
Figure 73. South America PEGylated Drugs Revenue Market Share by Countries in 2019
Figure 74. Brazil PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 75. Argentina PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 76. Middle East and Africa PEGylated Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa PEGylated Drugs Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa PEGylated Drugs Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa PEGylated Drugs Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 81. Egypt PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 82. Turkey PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 83. South Africa PEGylated Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 84. Global PEGylated Drugs Sales and Growth Rate (2021-2025) (K Units)
Figure 85. Global PEGylated Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales PEGylated Drugs Market Forecast (2021-2025) (K Units)
Figure 87. Europe Sales PEGylated Drugs Market Forecast (2021-2025) (K Units)
Figure 88. Asia-Pacific Sales PEGylated Drugs Market Forecast (2021-2025) (K Units)
Figure 89. South America Sales PEGylated Drugs Market Forecast (2021-2025) (K Units)
Figure 90. Middle East & Africa Sales PEGylated Drugs Market Forecast (2021-2025) (K Units)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel
PEG化医薬品の世界市場（～2026年） Market Analysis and Insights: Global PEGylated Drugs Market The global PEGylated Drugs market size is projected to reach US$ 7218.2 million by 2026, from US$ 7003.6 million in 2020, at a CAGR of 2.8%% during 2021-2026. Global PEGylated Drugs Scope and Market Size PEGylated Drugs market is segmented …- PEG化タンパク質治療薬の世界市場（～2026年） PEGylation is the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle. PEGylated protein therapeutics is estimated to show significant market growth during the forecast period, majorly due to the, growth …
- 腎臓/腎がん治療薬の世界市場（～2026年） Kidney/Renal Cancer Drugs are used to cure kidney cancers. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors bo…
- C型肝炎治療薬の世界市場（～2026年） Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc. Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepa…
- 筋萎縮性側索硬化症（ALS）治療薬の世界市場（～2026年） Amyotrophic lateral sclerosis is a neurodegenerative disease. ALS affects the nerve cells in the brain and spinal cord that control the voluntary muscles. It is also known as the Lou Gehrig’s disease. Amyotrophic lateral sclerosis can be caused due to various factors such as genetics or environmenta…